Update on the Cardiac Safety of Moxifloxacin Current Drug Safety, 2012, Vol. 7, No. 2 151 Table 1. Control Regimens Used in Phase II to IV Randomized Active-Controlled Studies with Moxifloxacin Included in this Pooled Analysis Indication PO studies IV/PO studies in CAP Control Regimens Amoxicillin 500 mg t.i.d. Amoxicillin 1000 mg t.i.d. Amoxicillin 1000 mg t.i.d. + clarithromycin 500 mg b.i.d. Amoxicillin 500 mg/clavulanate 125 mg t.i.d. Amoxicillin 875 mg/clavulanate 125 mg b.i.d. Amoxicillin 1000 mg/clavulanate 125 mg b.i.d. + roxithromycin 150 mg b.i.d. Azithromycin 250 mg q.d. Azithromycin 500 mg (first day)/250 mg q.d. (following days) Cefixime 400 mg q.d. Ceftriaxone (IM) 1000 mg q.d. Cefuroxime-axetil 250 mg b.i.d. Cefuroxime-axetil 500 mg b.i.d. Clarithromycin 250 mg b.i.d. Clarithromycin 500 mg b.i.d. Levofloxacin 100 mg t.i.d. Levofloxacin 200 mg b.i.d. Levofloxacin 500 mg q.d. Ofloxacin 200 mg b.i.d. Cephalexin 500 mg t.i.d. ± metronidazole 400 mg t.i.d. Doxycycline 100 mg b.i.d. + metronidazole 400 mg t.i.d. + ciprofloxacin 500 mg (single dose) Ofloxacin 400 mg b.i.d. + metronidazole 500 mg b.i.d. Trimethoprim 160 mg/sulfamethoxazole 800 mg b.i.d. Trovafloxacin 200 mg q.d. IV alatrofloxacin 200 mg q.d. then PO trovafloxacin 200 mg q.d. (initial phase)/IV levofloxacin 500 mg q.d. then PO levofloxacin 500 mg (continuation phase) IV amoxicillin 1000 mg/clavulanate 200 mg t.i.d. ± clarithromycin 500 mg b.i.d. then PO amoxicillin 500 mg/clavulanate 125 mg t.i.d. ± clarithromycin 500 mg b.i.d. IV ceftriaxone 2000 mg q.d. ± erythromycin 1000 mg t.i.d. or q.i.d. IV ceftriaxone 2000 mg q.d. + levofloxacin 500 mg b.i.d. then PO levofloxacin 500 mg b.i.d. IV ceftriaxone 2000 mg q.d. ± azithromycin 500 mg (first day)/250 mg q.d. (following days) ± metronidazole 500 mg q.i.d., then PO cefuroxime axetil 500 mg b.i.d. ± azithromycin 250 mg q.d. ± metronidazole 500 mg q.i.d. IV levofloxacin 500 mg q.d. then PO levofloxacin 500 mg q.d. IV/PO studies in cSSSI IV amoxicillin 1000 mg/clavulanate 200 mg t.i.d. then PO amoxicillin 500 mg/clavulanate 125 mg t.i.d. IV/PO studies in cIAI IV ceftriaxone 2000 mg q.d. + IV metronidazole 500 mg t.i.d. then PO amoxicillin 500 mg/clavulanate 125 mg t.i.d. IV piperacillin 3000 mg/tazobactam 375 mg q.i.d. then PO amoxicillin 800 mg/clavulanate 114 mg b.i.d. IV piperacillin 4000 mg/tazobactam 500 mg t.i.d. then PO amoxicillin 875 mg/clavulanate 125 mg b.i.d. IV piperacillin 3000 mg/tazobactam 375 mg q.i.d. then PO amoxicillin 800 mg/clavulanate 114 mg b.i.d. IV/PO studies in other indicationsa IV ampicillin 2000 mg/sulbactam 1000 mg t.i.d. then PO sultamicillin 750 mg b.i.d. IV ceftriaxone 2000 mg then PO cefuroxime axetil 500 mg b.i.d. PO = oral administration; IV = intravenous administration; IV/PO = sequential IV/oral administration; IM = intramuscular; q.d. = once daily; b.i.d. = twice daily; t.i.d. = three times daily; q.i.d. = four times daily; CAP = community-acquired pneumonia; cIAI = complicated intra-abdominal infections; cSSSI = complicated skin and skin structure infections. aAspiration pneumonia or lung abscess, hospital-acquired pneumonia.